Releases. In consideration of the mutual execution of this Agreement and the mutual agreement to be legally bound by the terms hereof, and other good and valuable consideration, Teva and Teva Canada, on the one hand, and Xenon, on the other hand, each on behalf of itself and any and all parent corporations, subsidiaries, affiliates, predecessors, successors, assigns, officers, directors, employees, attorneys, shareholders, and agents, do hereby mutually remise, release, covenant not to sue and forever discharge each other (and their agents and assigns) from and against all manner of actions, causes of action, suits, debts, accounts, promises, warranties, damages (including consequential or punitive damages), agreements, costs, interest, expenses, premiums, deductibles, claims or demands whatsoever, whether in law, equity, restitution or otherwise, in any jurisdiction (including but not limited to any rights, claims, or causes of action available by virtue of any statute or law in Canada or the United States), whether past, present or future, presently known or unknown, suspected or unsuspected, contractual or extra-contractual, asserted or unasserted, whether concealed or hidden, with respect to any and all past, present or future claims of any type whatsoever that they ever had now have, or hereafter may have against each other —except for any future claims Teva Canada hereafter may have relating to or arising from its ownership of Retained Stock, which are hereby excluded from this release—based upon, arising out of, in connection with, in consequence of, or in any way involving, arising under, relating to or in connection with the Collaboration Agreement or conducting or failing to conduct activities relating to the research, development, formulation, pre-clinical, non-clinical, clinical, testing and all other activities (including test method development, stability testing, toxicology studies, process development, statistical analysis and report writing, packaging, labelling and regulatory affairs, product approval and registration activities) relating to the Products. Notwithstanding the foregoing, nothing herein shall preclude, prevent or impair the right of any Party to bring a proceeding in court or any other forum for a breach of this Agreement, or any representation, warranty or covenant herein, or affect any of the Parties’ rights, obligations, or claims under this Agreement, including with respect to indemnification rights pursuant to Section 7 below.

Releases. The Agent is authorized to release any Lien granted to or held by it upon any Collateral # upon Payment in Full of all of the Obligations, # required to be delivered in connection with permitted sales or dispositions of Collateral hereunder, if any, upon receipt of the proceeds by the Agent (or, if permitted hereunder, the applicable Borrower) or # if the release can be and is approved by the Required Lenders. The Agent may request, and the Lenders will provide, confirmation of the Agent’s authority to release particular types or items of Collateral.

Releases. Except with respect to the obligations created by or arising out of this Agreement, and subject to payment to [[CAO:Organization]] of the Cash Payment as set forth in [Section 3.1] above, [[CAO:Organization]] does hereby for itself and its Affiliates and their respective legal successors, heirs and assigns, release and absolutely discharge the Biolase Entities, and their respective past, present and future owners, shareholders, parents, subsidiaries, successors, assigns, divisions, units, officers, directors, employees, agents, attorneys, and representatives (collectively, “Releasees”), of and from any and all claims, demands, damages, debts, liabilities, accounts, reckonings, obligations, costs, expenses, liens, attorneys’ fees, actions and causes of action of every kind and nature whatsoever, # arising out of or in connection with the Litigation (including the Patent Claims and the Non-Patent Claims) or the Licensed Patents, including all Claims, and/or # based in whole or in part on acts of the Biolase Entities prior to the Effective Date of this Agreement that would have been licensed (or covenanted not to sue) under this Agreement if performed after the Effective Date of this Agreement. Biolase does hereby for itself and its Affiliates and their respective legal successors, heirs and assigns, release and absolutely discharge the [[CAO:Organization]] Entities, and their respective past, present and future owners, shareholders, parents, subsidiaries, successors, assigns, divisions, units, officers, directors, employees, agents, attorneys, and representatives (collectively, “Releasees”), of and from any and all claims, demands, damages, debts, liabilities, accounts, reckonings, obligations, costs, expenses, liens, attorneys’ fees, actions and causes of action of every kind and nature whatsoever prior to the Effective Date of this Agreement, in connection with the licensing and enforcement of the Licensed Patents associated with the activities of Biolase, and any claims, counterclaims, or defenses that Biolase may have to any claim for infringement by [[CAO:Organization]] on any of the Licensed Patents.

Releases. On the 95ht day after payment of the Settlement Payment, if no bankruptcy petition has been filed by or against IGI before such 95th day, PBGC will be deemed to have released IGI from the Title IV Liabilities and its obligations under the Agreement, as modified by the First Amended Agreement.

Releases. At the Resignation Time, Executive, Company, Parent and Sole Member shall execute and deliver the mutual release agreement attached as [Exhibit C].

Releases.Each Co-Borrower hereby acknowledges that: # it has no defenses, claims or set-offs to the enforcement by Horizon or the Lenders of the Co-Borrowers’ liabilities, obligations and agreements on the date hereof; # to its knowledge, Horizon and the Lenders have fully performed all undertakings and obligations owed to it as of the date hereof; and # except to the limited extent expressly set forth in this Amendment, Horizon and the Lenders do not waive, diminish or limit any term or condition contained in the Loan Agreement or any of the other Loan Documents. Each Co-Borrower hereby waives, releases, remises and forever discharges Horizon and each Lender, its agents, employees, officers, directors, predecessors, attorneys, limited partners, managers, funding sources and all others acting or purporting to act on behalf of or at the direction of Horizon or such Lender (“Releasees”) from any and all claims, suits, actions, investigations, proceedings or demands, whether based in contract, tort, implied or express warranty, strict liability, criminal or civil statute or common law of any kind or character, known or unknown, which any Co-Borrower ever had or now has against the any of the Releasees which relates, directly or indirectly, to the Obligations, the Loan Agreement or the other Loan Documents or any acts or omissions of the Releasees in respect of the Obligations, the Loan Agreement or the other Loan Documents and arising from any event occurring on or prior to the date hereof. Without limiting the generality of the foregoing, the Co-Borrowers waive and affirmatively agree not to contest: # the right of Horizon or the Lenders to exercise its rights and remedies under the Loan Agreement or the other Loan Documents, or applicable law, or # any provision of this Amendment.

Releases. At such time as the Obligations shall have been paid in full, the Collateral shall be released from the Liens created hereby, and this Agreement and all obligations (other than those expressly stated to survive such termination) of the Indenture Trustee and the Guarantor hereunder shall terminate, all without delivery of any instrument or performance of any act by any party, and all rights to the Collateral shall revert to the Guarantor. At the request and sole expense of the Guarantor following any such termination, the Indenture Trustee shall deliver to the Guarantor any Collateral held by the Indenture Trustee hereunder, and execute and deliver to the Guarantor such documents as the Guarantor shall reasonably request and prepare to evidence such termination.

Releases. Purchaser shall have received acknowledgement and release agreements from each Stockholder in the form attached as Exhibit C;

Releases. In accordance with paragraph 2(a)(iii) of the Award Agreement, you hereby agree to the following Release:

Releases. For and in exchange for valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the following releases shall become effective upon [[Kaleyra:Organization]]’s payment of the Settlement Amount in accordance with Section 2 of this Agreement: